Clinical trial NCT03658213: To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.
Official title: An Open Label, Randomised, Parallel Group, Multicentre, Non-inferiority Study to Compare ZOLADEX 10.8 mg With ZOLADEX 3.6 mg in Chinese Pre-menopausal Patients With Estrogen Receptor-Positive and HER2 Negative Early Breast Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Breast Cancer
Keywords: Early breast cancer
Goserelin acetate
Estrogen suppression
Pre-menopausal
Zoladex
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2018-09-05
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will recruit 168 patients in approximately 20 study centres in China.

The primary objective of this study is to examine whether ZOLADEX 10.8 mg depot is non-inferior to ZOLADEX 3.6 mg depot in terms of the suppression rate of serum estradiol (E2) to the menopausal level (≤30 pg/mL) from Week 4 through Week 24.

Detailed description: This study will recruit 168 patients in approximately 20 study centres in China.

This open label, randomised, parallel group, multicentre study in Chinese pre menopausal patients with ER+/HER2- early breast cancer will be conducted to determine whether 3 monthly ZOLADEX 10.8 mg injection is non-inferior to monthly ZOLADEX 3.6 mg injection in terms of estradiol (E2) suppression. The study will also assess the PK, pharmacodynamics (PD), safety and tolerability of two difference strengths of ZOLADEX.

Eligible patients, as judged by the Investigator after completion of the screening tests, will be registered for this study and at the same time randomised in a 1:1 ratio to receive one of the following treatments. The study treatment must start within 7 days after randomisation.

* ZOLADEX 10.8 mg depot group: subcutaneous depot injection once every 12 weeks
* ZOLADEX 3.6 mg depot group: subcutaneous depot injection once every 4 weeks

The primary objective:

- To examine whether ZOLADEX 10.8 mg depot is non-inferior to ZOLADEX 3.6 mg depot in terms of the suppression rate of serum estradiol (E2) to the menopausal level (≤30 pg/mL) from Week 4 through Week 24.

The secondary objectives:

* To evaluate the safety and tolerability profiles of ZOLADEX 10.8 mg depot and ZOLADEX 3.6 mg depot.
* To evaluate the estradiol (E2) suppression by assessment of area under the curve (AUC) of E2 serum concentration during the 24 weeks of treatment.
* To evaluate the goserelin pharmacokinetics (PK) in Chinese patients after injection of ZOLADEX 10.8 mg depot and ZOLADEX 3.6 mg depot.
* To assess the influence on menstruous condition after injection of ZOLADEX 10.8 mg depot or ZOLADEX 3.6 mg depot.
* To assess the hormonal conditions after injection of ZOLADEX 10.8 mg depot compared with ZOLADEX 3.6 mg depot.

Eligibility criteria: Inclusion Criteria:

1. Provision of informed consent prior to any study specific procedures.
2. Women aged ≥18 at screening, in pre-menopausal status defined as:

   * Menses within 1 year before enrolment and within 3 weeks before enrolment, E2 \>30 pg/mL and FSH ≤40 mIU/mL.
   * Patients who received neo/adjuvant chemotherapy before randomisation should not having chemical menopause (Patients should meet: E2\>30pg/mL and FSH ≤40mIU/mL) within 12 weeks after completion of the postoperative chemotherapy.
3. Histologically confirmed ER+/HER2- primary invasive operable breast cancer (ER+ defined as at least 1% of the cells examined by immunohistochemistry testing have estrogen receptors).
4. Neoadjuvant chemotherapy and adjuvant chemotherapy prior to study enrolment are acceptable. (Please refer to Guidelines such as NCCN Clinical practice guidelines in oncology-breast cancer and CSCO-BC breast cancer guidelines for standard protocols and dosages. Please make accurate records.).
5. Have had proper surgery for primary breast cancer with no known clinical residual loco regional disease.
6. World Health Organization (WHO) performance status of 0, 1, or 2.
7. Female patients of child bearing potential and their partners, who are sexually active, must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for at least 3 month after last dose of Zoladex or Tamoxifen which happens later, or they must totally/truly abstain from any form of sexual intercourse.

Exclusion Criteria:

1. Any evidence of metastatic disease.
2. Have received other previous neo/adjuvant endocrine therapy for breast cancer.
3. Other malignancy within the last 3 years except adequately treated basal cell/squamous cell carcinoma of the skin or cancer of the cervix.
4. Have any unstable complication or uncontrolled infection during screening.
5. Patients considered at poor medical risk due to a serious, uncontrolled medical disorder, non malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, extensive bilateral lung disease on High Resolution Computed Tomography scan or any psychiatric disorder that prohibits obtaining informed consent.
6. Postmenopausal woman, defined as a woman fulfilling any of the following criteria:

   * Having undergone a bilateral oophorectomy
   * Age ≥60 years
   * Age \<60 years and amenorrheic for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene or ovarian suppression and FSH and oestradiol level in the postmenopausal range (utilising ranges from the local laboratory facility)
   * If taking tamoxifen or toremifene, and age \< 60 years, then FSH and plasma oestradiol level in the postmenopausal ranges (utilising ranges from the local laboratory facility)
7. Have had a bilateral oophorectomy or ovarian irradiation.
8. HER2 overexpression or gene amplification, i.e., immunohistochemistry (IHC)3+ or fluorescence in situ hybridisation (FISH)+, where appropriate
9. Screening test results of:

   * Platelets \<100 × 109/L
   * Total bilirubin \>1.5 × upper limit reference range (ULRR)
   * Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \>2.5 × ULRR
10. Any other significantly abnormal laboratory test result at screening that would place the patient at unusual risk or confound the results of the study.
11. Patients with a relevant history of any severe concomitant disease that would place the patient at unusual risk or confound the results of the study, e.g., a strong family history of osteoporosis or severe renal or hepatic impairment.
12. Patients who, for whatever reason (e.g., confusion, infirmity, alcoholism) are unlikely to comply with study requirements as judged by the Investigator(s).
13. Patients considered by the Investigator(s) to be at risk of transmitting any infection through blood or other body fluids including the agents for acquired-immune deficiency syndrome (AIDS) or other sexually transmitted disease or hepatitis.
14. History of bleeding diathesis (i.e., disseminated intravascular coagulation \[DIC\] or clotting factor deficiency) or long-term anti-coagulant therapy (other than anti platelet therapy and low dose warfarin).
15. History of any hypersensitivity to active or inactive excipients of LHRH agonist or tamoxifen.
16. Patients unwilling to stop taking any drug that affects sex hormonal status, or in whom it would be inappropriate to stop.
17. Participation in another clinical study with an investigational product during the last 30 days.
18. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study centre).
19. Previous enrolment or randomisation of treatment in the present study.
20. Female patients who are pregnant or breast-feeding.

Primary outcomes:
measure: Effective inhibition rate of serum estradiol(E2)
timeFrame: At scheduled visits from Week 4 through Week 24.
Secondary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
timeFrame: From screening to 4 weeks after the completion of 24 weeks treatment period.
measure: Change in Alanine aminotransferase(U/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Aspartate aminotransaminase(U/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Albumin(g/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Alkaline phosphatase(U/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Calcium(mmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Creatinine(μmoI/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in High density lipoprotein cholesterol(mmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Inorganic phosphate(mmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Low density lipoprotein cholesterol(mmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Plasma glucose(mmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Potassium(mmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Lactate dehydrogenase(U/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Triglyceride(mmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Sodium(mmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Total bilirubin(μmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Total cholesterol(mmol/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Absolute neutrophil count(/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Haematocrit(vol%)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Haemoglobin(g/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Mean cell volume(fl)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Platelet count(/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in White blood cell count (total)(/L)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Systolic Blood Pressure(mmHg)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Diastolic blood pressure(mmHg)
timeFrame: At scheduled visits from screening to 24th week.
measure: Change in Heart rate(bpm)
timeFrame: At scheduled visits from screening to 24th week.
measure: To evaluate the estradiol (E2) suppression by assessment of area under the curve (AUC) of E2 serum concentration.
timeFrame: At scheduled visits from screening to 24th week.
measure: Observed maximum Goserelin plasma concentration (Cmax)
timeFrame: At scheduled visits from treatment start to treatment completion (week 24th).
measure: Time to maximum Goserelin plasma concentration (tmax)
timeFrame: At scheduled visits from treatment start to treatment completion (week 24th).
measure: Area under the Goserelin plasma concentration-time curve from time zero to time of the last measurable concentration (AUCt)
timeFrame: At scheduled visits from treatment start to treatment completion (week 24th).
measure: Area under the Goserelin plasma concentration-time curve from time zero to 4 weeks (AUC (0-4 weeks))
timeFrame: At scheduled visits from treatment start to 4 Weeks.
measure: Area under the Goserelin plasma concentration-time curve from time zero to 12 weeks (AUC (0-12 weeks))
timeFrame: At scheduled visits from treatment start to 12 Weeks.
measure: Trough concentration (Ctrough)
timeFrame: At scheduled visits from treatment start to treatment completion (24th week).
measure: The rate of participants who had menstruation.
timeFrame: At scheduled visits from screening to treatment completion (24th week), approximately 27 weeks.
measure: E2 serum concentrations
timeFrame: At scheduled visits from screening to treatment completion (24th week), approximately 27 weeks.
measure: FSH serum concentrations
timeFrame: At scheduled visits from screening to treatment completion (24th week), approximately 27 weeks.
Other outcomes:
Locations:
city: Beijing
country: China
facility: Research Site
city: Chengdu
country: China
facility: Research Site
city: Guangzhou
country: China
facility: Research Site
city: Guangzhou
country: China
facility: Research Site
city: Hangzhou
country: China
facility: Research Site
city: Hangzhou
country: China
facility: Research Site
city: Harbin
country: China
facility: Research Site
city: Shanghai
country: China
facility: Research Site
city: Shenyang
country: China
facility: Research Site
city: Shijiazhuang
country: China
facility: Research Site
city: Tianjin
country: China
facility: Research Site
Study officials:
affiliation: 307 Hospital of PLA
name: Zefei JIANG
role: PRINCIPAL_INVESTIGATOR
References: